Browsing Tag
AstraZeneca
162 posts
AstraZeneca’s breakthrough in lung cancer treatment: Datopotamab deruxtecan achieves promising survival rates
AstraZeneca’s datopotamab deruxtecan (Dato-DXd), a cutting-edge TROP2-directed antibody-drug conjugate, has demonstrated encouraging overall survival results in the TROPION-Lung01…
EC approves AstraZeneca’s Tagrisso with chemotherapy for EGFR-mutated lung cancer
AstraZeneca has received approval from the European Commission (EC) to use its cancer drug, Tagrisso (osimertinib), in combination…
AstraZeneca’s CALQUENCE demonstrates enhanced efficacy in mantle cell lymphoma trial
AstraZeneca has announced significant outcomes from the ECHO Phase III trial, highlighting the effectiveness of its drug CALQUENCE…
AstraZeneca secures Fusion Pharmaceuticals in $2.4bn deal to advance cancer treatment
AstraZeneca has finalized the acquisition of Fusion Pharmaceuticals Inc., a significant move valued at approximately $2.4 billion, designed…
Tempus and AstraZeneca expand collaboration to enhance cancer care with AI
Tempus, a pioneer in artificial intelligence and precision medicine, has announced an expansion of its collaboration with pharmaceutical…
AstraZeneca acquisition of Fusion Pharmaceuticals receives shareholder approval
In a significant step towards finalizing the acquisition, Fusion Pharmaceuticals Inc.’s shareholders have overwhelmingly voted in favor of…
Datopotamab deruxtecan shows promise in Phase III trial for NSCLC
AstraZeneca and Daiichi Sankyo have announced promising results from the TROPION-Lung01 Phase III trial, highlighting datopotamab deruxtecan’s potential…
COURSE trial reveals promising results for TEZSPIRE in COPD patients with high eosinophil counts
In a significant development in chronic obstructive pulmonary disease (COPD) management, the Phase IIa COURSE trial, a proof-of-concept…
AstraZeneca withdraws COVID-19 vaccine amid legal challenges and commercial decisions
In a significant development, UK-based pharmaceutical giant AstraZeneca has announced the global withdrawal of its COVID-19 vaccine, known…
ANGLE plc signs deal with AstraZeneca to develop Parsortix-based AR detection assay for prostate cancer studies
In a deal valued at ÂŁ550,000, ANGLE plc (AIM:AGL, OTCQX:ANPCY), a leading liquid biopsy company specializing in circulating…